Eyeworld

2 Meibography Summit: Translating knowledge into practice and catch them before that," Dr. Gupta said. Kim et al. showed that 82% of patients using glau- coma medications had MGD, and Mocan et al. reported that obstructive MGD was seen in approximately 96% of topical prostaglandin analog users. 5,6 Cochener et al. stated that 52% of patients having cataract surgery had MGD and 56% had gland atrophy. 7 Trattler et al. found that approximately 77% of patients having cataract sur- gery had fluorescein staining. 8 with meibomian gland dysfunction. J Glaucoma. 2016;25:770–4. 7. Cochener B, et al. Prevalence of mei- bomian gland dysfunction at the time of cataract surgery. J Cataract Refract Surg. 2018;44:144–148. 8. Trattler WB, et al. The Prospective Health Assessment of Cataract Patients' Ocular Surface (PHACO) study: the effect of dry eye. Clin Ophthalmol. 2017;11:1423–1430. 9. Epitropoulos AT, et al. Effect of tear osmolarity on repeatability of keratom- etry for cataract surgery planning. J Cataract Refract Surg. 2015;41:1672–7. 2. Lemp MA, et al. Distribution of aque- ous-deficient and evaporative dry eye in a clinic-based patient cohort: a retro- spective study. Cornea. 2012;31:472–8. 3. Patel S, et al. Effect of visual display unit use on blink rate and tear stability. Optom Vis Sci. 1991;68:888–92. 4. Gupta PK, et al. Prevalence of meibomian gland atrophy in a pediatric population. Cornea. 2018;37:426–430. 5. Kim JH, et al. Eyelid changes related to meibomian gland dysfunction in early middle-aged patients using topical glaucoma medications. Cornea. 2018;37:421–425. 6. Mocan MC, et al. The association of chronic topical prostaglandin analog use Early intervention Early diagnosis and treatment are critical. Otherwise, patients have a chronic condition that leads to OSD and vision problems and potentially worse outcomes from refractive or cataract surgery, said William Trattler, MD. 9 References 1. Nelson JD, et al. The Internation- al Workshop on Meibomian Gland Dysfunction: report of the Definition and Classification Subcommittee. Invest Ophthalmol Vis Sci. 2011; 52:1930– 1937. OCuSOFT, and is a board member for Ophthalmic Resources. Eric Donnenfeld, MD, has an investment interest in, has received a retainer, ad hoc fees, or other consulting income from, is a member of the speakers bureau of, and has received research funding from: AqueSys, Autofocus, Avedro, Elenza, Glaukos, Katena, LensGen, Mati Pharmaceuticals, Mimetogen, NovaBay, OcuHub, Pogotec, RPS, SARcode, Strathspey Crown, TearLab, TrueVision, Veracity, Versant Ventures, and Visionary Ventures. He has received a retainer, ad hoc fees, or other consulting income from: AcuFocus, Allergan, Bausch + Lomb, CRST, Foresight, Icon Biosciences, Johnson & Johnson Vision, Kala, Merck, Novaliq, Odyssey, and Oys. Alice Epitropoulos, MD, has property rights/is the patent holder of a relevant ophthalmic device from Eye Care and Cure. She has received a retainer, ad hoc fees, or other consulting income from Alcon, Allergan, Bausch + Lomb, BlephEx, Johnson & Johnson Vision, NovaBay, Omeros, PRN, RPS, Shire, Sun Pharmaceuticals, and TearLab. She has received research funding from Bausch + Lomb, Kala, Ocular Therapeutix, PRN, and TearLab. Marjan Farid, MD, has received a retainer, ad hoc fees, or other consulting income from: Allergan, BioTissue, Johnson & Johnson Vision, Kala, and Shire. Accreditation Statement This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the American Society of Cataract and Refractive Surgery (ASCRS) and EyeWorld. ASCRS is accredited by the ACCME to provide continuing medical education for physicians. Educational Objectives Ophthalmologists who participate in this activity will: • Cite the incidence of MGD • Describe the impact of MGD on outcomes • Assess meibomian gland structure and function, and why meibography should be integrated as a part of the initial point-of-care workup • Increase confidence in making therapeutic decisions for patients with variable stages of MGD Designation Statement The American Society of Cataract and Refractive Surgery designates this enduring materials edu- cational activity for a maximum of 1.0 AMA PRA Category 1 Credits.™ Physicians should claim only credit commensurate with the extent of their participation in the activity. Claiming Credit To claim credit, participants must visit bit.ly/2Pfph7m to review content and download the post-activity test and credit claim. All partici- pants must pass the post-activity test with a score of 75% or higher to earn credit. Alternatively, the post-test form included in this supplement may be faxed to the number indicated for credit to be awarded, and a certificate will be mailed within 2 weeks. When viewing online or downloading the material, standard internet access is required. Adobe Acrobat Reader is needed to view the mate- rials. CME credit is valid through March 31, 2019. CME credit will not be awarded after that date. Notice of Off-Label Use Presentations This activity may include presentations on drugs or devices or uses of drugs or devices that may not have been approved by the Food and Drug Administration (FDA) or have been approved by the FDA for specific uses only. ADA/Special Accommodations ASCRS and EyeWorld fully comply with the legal requirements of the Americans with Disabilities Act (ADA) and the rules and regulations thereof. Any participant in this educational program who requires special accommodations or services should contact Laura Johnson at ljohnson@ascrs. org or 703-591-2220. Financial Interest Disclosures Frank Bowden III, MD, FACS, has received a retainer, ad hoc fees, or other consulting income from Allergan, Johnson & Johnson Vision, Kala Pharmaceuticals, and Shire. Alan Carlson, MD, has an investment interest in iVeena and TearScience/Johnson & Johnson Vision. He has received a retainer, ad hoc fees, or other consulting income from TearScience/Johnson & Johnson Vision. He is a member of the speakers bureau of Alcon, Med1, and STAAR Surgical. Douglas Devries, OD, has an investment interest in Revision Optics and RPS. He has received a retainer, ad hoc fees, or other consulting income from and is a member of the speakers bureau of: Allergan, Bausch + Lomb, Beaver-Visitec International, BioTissue, EyeGate Pharmaceuticals, Johnson & Johnson Vision, Science Based Health, Shire, and TearLab. He has received a retainer, ad hoc fees, or other consulting income from Bruder, Eyes 4 Lives, and RySurg. He is a member of the speakers bureau of Sun Pharmaceuticals and continued from page 1 Figure 1. All Meibography Summit respondents think that at least 60% of cataract surgery candidates have MGD. In your clinic, what percentage of cataract surgery candidates have MGD? Meibography Summit Figure 2. Most respondents think that more than 75% of their OSD patients have MGD. In your clinic, what percentage of your overall OSD patients have MGD? Meibography Summit

• Cover